Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Camrelizumab
Indication/Tumor Type nasopharynx carcinoma
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown nasopharynx carcinoma not applicable Camrelizumab Phase I Actionable In a Phase I trial, Camrelizumab (SHR-1210) treatment was well tolerated in patients with refractory nasopharyngeal carcinoma, and demonstrated preliminary efficacy with an overall response rate of 34% (31/91, 2 complete responses and 29 partial responses) and a disease control rate of 59% (54/91, stable disease or better) (PMID: 30213452; NCT02721589). 30213452
Unknown unknown nasopharynx carcinoma not applicable Camrelizumab Phase I Actionable In a Phase I trial, Camrelizumab (SHR-1210) demonstrated safety and preliminary anti-tumor activity, resulted in partial response in 33.3% (1/3) of patients with nasopharynx cancer (J Clin Onc. 2017 35:15_suppl, e15572-e15572; NCT02742935). detail...
PubMed Id Reference Title Details
Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors. Full reference...
(30213452) Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Full reference...